Chemotherapy
599 articles
Research Updates from ASCO GI 2023
Read the latest clinical trial and research updates from the 2023 ASCO GI meeting, including a review of genetic testing uptake.
ASCO 2023: Pancreatic Cancer Research Update
The pancreatic cancer research reports from ASCO 2023 focused on different chemotherapy combinations, including immunotherapy.
Comparing Chemotherapy Before with Chemotherapy After Pancreatic Cancer Surgery
Researchers are comparing effectiveness of chemotherapy before surgery (neoadjuvant) with chemotherapy after surgery (adjuvant).
Research Highlights from ASCO GI 2026
The latest research on drugs targeting KRAS and new immuotherapy combinations were among the highlights of ASCO GI 2026.
New Study Shows Benefit of Chemotherapy after Surgery
Should you have adjuvant chemotherapy–treatment after pancreatic cancer surgery? Dr. Marco Del Chiaro explains that the evidence says “yes.”
Pancreatic Cancer Research Highlights from ASCO Annual Meeting
The 2025 ASCO meeting featured pancreatic cancer research including a new treatment modality and a new treatment combination.
Chemotherapy Plus Minimally Invasive Surgery for Pancreatic Cancer
Researchers want to know if irreversible electroporation (IRE) makes it easier for chemotherapy to reach pancreatic cancer cells.
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
Chemotherapy Plus Immunotherapy Trial Shows Promise
Dr. Gulam Manji leads a clinical trial that uses two types of immunotherapy to enhance chemotherapy for pancreatic cancer patients.
Canadian Study NeoPancONE Focuses on Biomarker Validation
Dr. Jennifer Knox is leading the NeoPancONE trial for a biomarker that indicates which patients will respond better to certain chemotherapy before surgery.
Targeting AXL May Improve Chemotherapy for Pancreatic Cancer
Dr. Shaalan Beg describes a clinical trial using the kinase inhibitor bemcentinib along with chemotherapy as a way to slow down or stop pancreatic cancer.
Pancreatic Cancer Research Updates from ASCO 2024
Learn about the latest developments in pancreatic cancer research into immunotherapy and chemotherapy from the ASCO 2024 meeting.
Final Results of the Daraxonrasib Trial Are Unprecedented
When Dr. Brian Wolpin read the final results from the phase III daraxonrasib trial, everyone was on their feet at the 2026 ASCO meeting.
Advances in Pancreatic Neuroendocrine Tumor (PNET) Treatments
Dr. Diane Reidy-Lagunes outlines the current state of treatments for pancreatic neuroendocrine tumors (PNETs).
PARP Inhibitors for Pancreatic Cancer Maintenance Treatment
Dr. Kim Reiss Binder is leading a clinical trial of maintenance treatment with the PARP inhibitor rucaparib, for patients who carry the BRCA mutation.